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Summary
Aircrew are responsible for safe and reliable aircraft operations. Cardiovascular disease accounts for 50% of all pilot licences declined or
withdrawn for medical reasons in Western Europe and is the most common cases of sudden incapacitation in flight. Aircrew retirement
age is increasing (up to age 65) in a growing number of airlines and the burden of subclinical, but potentially significant, coronary athero-
sclerosis is unknown in qualified pilots above age 40. Safety considerations are paramount in aviation medicine, and the most dreaded
cardiovascular complications are thromboembolic events and rhythm disturbances due to their potential for sudden incapacitation. In avi-
ation, the current consensus risk threshold for an acceptable level of controlled risk of acute incapacitation is 1% (for dual pilot commercial
operations), a percentage calculated using engineering principles to ensure the incidence of a fatal air accident is no greater than 1 per
107 h of flying. This is known as the ‘1% safety rule’. To fly as a pilot after cardiac surgery is possible; however, special attention to periopera-
tive planning is mandatory. Choice of procedure is crucial for license renewal. Licensing restrictions are likely to apply and the postopera-
tive follow-up requires a tight scheduling. The cardiac surgeon should always liaise and communicate with the pilot’s aviation medicine
examiner prior to and following cardiac surgery.
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INTRODUCTION
The medical regulatory process for aircrew
The determination of an individual’s ability to fly after a surgical
procedure falls under the field of aviation medicine and different
restrictions apply to aircrew (pilots, navigators, air traffic controllers
and other professionals who operate in the aviation environment)
and passengers. The assessment of aircrew requires specific aviation
medicine training and certification from both the national and the
supranational aviation agencies [e.g. Civil Aviation Authority (CAA)
in the UK, Federal Aviation Administration (FAA) in the USA and
European Aviation Safety Agency (EASA) for the European
Continent]. A licensed aeromedical examiner (AME) is the primary
medical person who assesses aircrew [1–3], albeit nowadays the UK
CAA enables general practitioners to assess (non-commercial) light
aircraft pilots [4]. The AME, as a general aviation medicine specialist
is also a valuable resource who may assist surgeons, both when
determining the most appropriate surgical management of aircrew
and when determining the postoperative timescale for patients to
fly as both passengers and aircrew. Professional pilots hold Class I
licenses, recreational pilots Class II, with differing medical standards
required to be met to be eligible. In the civil environment restric-
tions on licenses include Operation Multicrew License (OML) for
Class I or Operational Safety License (OSL) for Class II, mandating a
second pilot qualified on type to be present, and able to take
control, in the event of acute incapacitation. In aviation, the cur-
rent consensus risk threshold is known as the ‘1% safety rule’ (Fig. 1)
[1, 3]. Military aircrew clearance is usually significantly more restrict-
ive than that for civil regulations.
The aviation environment
The flight deck is a unique and demanding working environment,
especially in military aviation and aerobatics. In addition to the
high inherent cognitive demand placed on aircrew (and particu-
larly pilots), one must also consider additional factors that may
degrade physical performance such as acceleration forces in both
civil and military high-performance flight and mission pressure,
enemy threat and sleep deprivation in the military environment.
Acceleration (or Gz) is a gravitational force that, in flight, is usually
applied to the vertical axis of the body. If it is experienced from
head to foot (positive Gz), it is termed +Gz. Additional positive Gz
is experienced when a pilot pulls out of a dive or pulls into an
inside loop [5]. The high +Gz environment is an exceptional
physiological parameter that places a significant physiological
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cardiovascular burden on the heart and that requires thoughtful
consideration in all stages of surgical management.
To perform competently in this unique environment requires high
cardiac output, optimal coronary flow profiles and best transvalvular
gradient profiles. In military aviation and aerobatics, +Gz-loads repre-
sent an exceptional physiological strain on the cardiovascular system
to maintain vital cerebral, coronary and myocardial perfusion under
unusual attitudes (Fig. 2). As an example, we know that aortic valve
bioprostheses display different flow characteristics and gradient slope
curves under low- and high-flow conditions [6, 7], and it is this type
of data that is critical in the management of aircrew who present for
cardiac surgery.
Cardiothoracic surgical considerations in pilots
It is possible to return to flying as a pilot after cardiac surgery; how-
ever, special attention to perioperative planning is essential; choice
of procedure (e.g. full revascularization) and prosthetic material (e.g.
stentless or haemodynamically improved stented bioprostheses)
are often critical in the determination of license renewal.
Restrictions on pilot licenses are likely to apply following surgery
and postoperative follow-up usually requires intensive additional
investigations at specific time points. The cardiac surgeon should al-
ways liaise with the pilot’s AME prior to the operation and under-
stand the ramifications of different courses of action, and the need
for certain clinical investigations to allow the AME to determine
their suitability to return to their flying career or recreation.
As a general principle, the authors recommend that the most
appropriate, evidence-based, surgical intervention should always
be offered, ensuring that the pilot is aware of the ramifications of
this suggestion to their professional role. If unacceptable to the
pilot, however, the surgeon should be willing to offer aircrew al-
ternative options (that may differ from usual practice). These
should still be clinically appropriate but allow these professionals
the opportunity to continue with their professional careers (even
if limited). Pilots should be aware of the additional risks that
might be associated with these alternative courses of action, but
as long as an informed decision is agreed between the surgeon
and pilot, informed consent is maintained.
Confirming flight licensing after cardiac surgery is a challenge for
both the cardiac surgeon and the AME. Only the AME is authorized
to determine the flight status of pilots [3]. In Europe, EASA releases
the medical regulations for flight crew licensing in a specific docu-
ment, the Part-MED [8, 9]. In contrast to the surgical and cardiolo-
gical guidelines, aviation authorities update their regulations at a
slower pace, as they need to be synchronized with a multitude of
legislation in individual countries. These standards represent the
legal framework with which AMEs and surgeons have to comply.
Although the European Society of Cardiology (ESC)/European
Association for Cardio-Thoracic Surgery (EACTS)/American Heart
Association (AHA) [10, 11] guidelines and recommendations are
usually familiar to all surgeons, the Part-MED represents a further
legally binding series of regulations that the surgeon should be cog-
nisant with when operating on professional aircrew.
For pilots undergoing cardiac surgery, there are many limitations
related to both the surgical intervention and to the post-surgical
therapeutic options. Anticoagulation remains a disqualifying condi-
tion for most commercial pilots, and partial revascularization would
often also lead to a loss of flight license in many countries. High
+Gz loads induce mediastinal shifts (Fig. 2), potentially impacting on
graft flows and prosthetic valve function. As no randomized studies
exist in this field due to the small, often younger, specialist cohort,
the AMEs and surgeons have to rely on understanding of the phys-
ics of the aviation environment, cardiovascular physiology in this
environment and a good dose of common sense.
METHODS
Study design
To underpin this review, we performed a focused systematic review
of current aeronautical and related surgical literature. We screened
the Medline database with the keywords (English language only)
Figure 1: Calculation of the 1% safety rule, from [1, 3].
Figure 2: Monkey in centrifuge: chest X-rays of a chimpanzee undergoing centri-
fuge testing at + 1Gz, +2Gz, +4Gz and +6Gz. Mediastinal elongation with topographic
changes [30].
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‘aortic—aorta—valve—coronary artery—bypass grafting—surgery—
pilot—air crew—licensing’ and established a threshold time cut-off
including the publication year 1993 for literature review and 2008
for Flight Crew Licensing Regulations. We reviewed the latest EASA
and International Civil Aviation Organization (ICAO) flight crew
licensing regulations as well as the previous releases from the Joint
Aviation Authority (JAA). We additionally reviewed airline’s current
operation procedures. Where applicable, we added selected aspects
of our respective Air Forces’ Operating Manuals (English, German
and French languages).
Specific aspects of flight crew licensing literature
Contemporaneous literature, especially peered reviewed, is
scarce in aviation medicine. Most of the information is to be
found in manuals from the respective national authorities
(such as UK Civil Aviation Authority and US Federal Aviation
Administration) and supranational regulatory bodies (such as
the EASA). Military aviation medicine publications are more
secretive and intentionally not shared broadly. Our group felt
that the review of the available peer-reviewed literature and
from our respective national publications (civil and air force)
provides the highest possible level of actual information
matching into 1 single manuscript.
RESULTS
In Europe, all cardiac surgery cases in pilots must be evaluated
by an AME, the operating surgeon and a cardiologist postopera-
tively and will not be considered for a return to flight duties
earlier than 6 months [8] following surgery and full assessment.
All guidelines consider the high +Gz load environment and
stress the importance of considering the effect of sustained
Valsalva manoeuvres and high cardiac output. They all reiterate
the need for optimal communication and co-ordination be-
tween the cardiac surgeon and the pilot’s AME and state its cen-
tral importance to the management of this professional group.
This article summarizes the key parameters that permit a safe
return to flight duties in accordance with the existing guidance
material [1, 8] after cardiac surgery. This includes valve disease
(general, aortic and mitral valve surgeries), coronary artery
bypass grafting (CABG) surgery, aortic surgery and surgical
intervention for genetic and congenital cardiac diseases. It is
worth noting that many of the sections within the EASA regula-
tions are controversial and differ significantly from clinical
recommendations and standard practice in non-aircrew
populations.
General considerations and regulations that apply to all air-
crew following surgery include the requirement for no postoper-
ative reduction in cardiac function (ejection fraction of 50% is
usually the minimal accepted standard), and cardiac chamber di-
mensions are within normal limits and no aviation-relevant path-
ology is left untreated, even if usual clinical practice would deem
it clinically of less significance. Aircrew are usually required
to undertake their flight duties off most, if not all, postoperative
cardioactive medications, especially if undertaking solo flight op-
erations or high-performance flight (exceptions may include
angiotensin-converting enzyme inhibitors and angiotensin II
receptor blockers).
Valve disease in aircrew
Because of the nature of the aviation environment, it is necessary
to maintain cardiac output under high preload conditions and any
restrictions to cardiac output (chronotropic and inotropic re-
sponse or fixed obstruction due to stenotic valve lesions) are
poorly tolerated, meaning even mild stenosis may be prohibitive
in high-performance flight. Mild regurgitant valve lesions are of
less concern, but any lesion that impacts on ventricular function,
increases arrhythmia risk or reaches moderate severity is likely to
result in professional flying restrictions. Additionally, it appears
that younger patients undertaking active flight duties have a higher
prevalence of bicuspid aortic valve disease requiring surgery than
age-matched non-aircrew [12, 13]. As previously discussed, antico-
agulation still is often a disqualifying condition, especially in mili-
tary aviation, although EASA has loosened its civil restrictions in
recent years, to the concern of many aviation medicine practi-
tioners who have concerns that both the bleeding and thrombosis
risk associated with anticoagulants often fall outside the 1% rule.
Aortic valve surgery. Pilots undergoing aortic valve surgery
face many limitations that restrict both the surgical and medical
therapeutic options available to the surgeon, if the pilot is to con-
tinue to fly. Due to the ramifications of a limited cardiac output,
aircrew may present with mild-to-moderate disease that would
not usually be considered for surgery. If accepted for surgery, the
restriction placed on aircrew with regard to the use of anticoagu-
lation, meaning that mechanical valves are discouraged, even in
young patients. The implanting surgeon must also pay close at-
tention to the choice of prosthetic material, and it is strongly sug-
gested that they consider preference for stentless devices [6, 7] or
haemodynamically improved newer stented bioprostheses.
It is accepted that structural valve disease is the main issue in
maintaining long-term fitness to fly; the 2012 ESC/EACTS
guidelines on the management of valvular heart disease suggest
that surgeons should plan any reoperation early to minimize any
loss of license due to medical conditions and plan the reopera-
tion ahead of the development of clinical symptoms. (Class IIa/
Level C indication) and states: ‘AVR should be recommended in
asymptomatic patients’ [14].
Following aortic valve surgery, additional restrictions will usu-
ally apply to pilots and there are minimum requirements for
follow-up that must be adhered to, to retain licenses. Licensing
requirements for aortic valve surgery mandate a bioprosthesis
and will only consider a return to flying in those with no postop-
erative restrictions in cardiac function, off all postoperative cardi-
oactive medications. Aortic surgeons must appreciate the central
importance of prostheses with high-flow profile, such as stentless
implants or newer haemodynamically improved stented biopros-
theses. Furthermore, stentless implants may be preferred when
applicable over stented ones due to their potentially improved
coronary flow profile [6, 7, 15–17]. Professional pilots with Class 1
licenses may be restricted to multipilot operations (Class 1 OML)
and those with Class 2 licenses may require a safety pilot (Class 2
OSL).
Licensing will exclude high +Gz environments, usually over
+3Gz, and usually exclude ejection seat aircraft, (although low-
performance delivery flights, where aircraft are not flown to their
usual capability may be allowed).
It should be noted that EASA have studied the possibility of
permitting mechanical valves for non-professional pilots. Since
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2011, EASA have been considering defining ‘stable antico-
agulation’ as >_5 international normalized ratio (INR) values within
the normal range the last 6 months, where the target range of
each particular implanted device was met in >_4 of these INR
measurements. This debate continues with strong advocates on
both sides of the argument.
The minimum follow-up schedule after aortic valve surgery for
aircrew includes an initial 6-month postoperative follow-up with
subsequent review according to age and Part-MED plan. These
consultations are required every 6 months for both Class 1 and
Class 2 pilots over 40 years in a single-pilot commercial air trans-
port operations with passengers and for all pilots over 60 years
old. These reviews must be conducted by a cardiologist accept-
able to the national aeromedical section (AMS). Follow-up inves-
tigations after aortic valve surgery are outlined in Table 1.
Mitral valve surgery. Mitral valve surgery may be required in
any aircrew with moderate regurgitation or in those with abnor-
mal ventricular dimensions, or function, secondary to valve dis-
ease. Mitral valve replacement is usually a disqualifying procedure.
This was stated in the ICAO regulations in 2008 but is no longer
mentioned in the current EASA guidelines. Return to flying duties
is possible following mitral leaflet repair, provided that LV function
is satisfactory, LV systolic and diastolic dimensions are not
increased and that there is not more than minor residual mitral re-
gurgitation postoperatively. Importantly, when undertaking mitral
valve repair, surgeons should consider left atrial appendage (LAA)
exclusion (due to the incapacity risk associated with thromboem-
bolic disease). However, it should be noted that the guidelines
surrounding LAA excision in aircrew are inconsistent in the regula-
tory literature. These state that return to flying is permitted only
when LAA ‘resected’ (JAR FCL-3 2002) that LAA amputation ‘may
be’ an advantage (ICAO 2008) or not mentioned at all (EASA
Part-MED 2011).
Coronary artery bypass grafting
Aircrew with proven significant coronary artery disease (CAD) re-
quire ‘complete’ revascularization [no stenosis >70% left untreated,
respectively, >50% for left main stem (LMS)] to ensure that, after
intervention, those without symptoms have reduced any vascular
risk within the 1% rule. In the context of aviation, a very low post-
revascularization major adverse cardiac event rate is needed be-
fore certification and licensing can be considered. This requires a
different approach to standard CABG or percutaneous coronary
intervention (PCI) in that even moderate bystander disease may
require intervention to ensure relicensing is possible. Note that for
PCI a ‘complete’ revascularization is compulsory for consideration
to revalidation. PCI in diabetic patients should not be acceptable
due to the high subsequent event rate. Furthermore, in multivessel
disease, PCI reaches less complete revascularization than surgery
[1, 10]. No surgical evidence supports revascularization of stenosis
<70% (<50% for the LMS) in any vessel including graft; neither
does it apply to PCI. Radial artery should not be used to graft sten-
oses less than critical (<90%) [18, 19].
As with valve surgery, all aircrew require an initial 6-month re-
view, and if they fulfil the regulatory criteria this will allow a re-
turn to flying with a multipilot limitation (OML or OSL in civil
flight operations). The usual investigation schedule is shown in
Table 2. Any anti-anginal medication, when used to control car-
diac symptoms, is not acceptable if pilots wish to return to flying
duties. All aircrew should be on acceptable and aggressive sec-
ondary prevention treatment. Subsequent follow-up should be at
minimum annually and include at least a review by a cardiologist,
following an exercise ECG and full cardiovascular risk assessment.
To fulfil the regulatory criteria following revascularization, a cor-
onary angiogram obtained at the time of, or during, the ischaemic
myocardial event and a complete detailed clinical report of the is-
chaemic event and operative procedure must be available to the
licensing authority [10]. The criteria that must be met include the
following: (i) no stenosis >50% in any major untreated native vessel
or graft or stent and (ii) no more than 2 stenoses >_30 but <_50%
within the vascular tree. Depending on the threshold levels of
stenosis and their localization (LMS, proximal LAD etc.), aircrew
may have to undergo anatomic reassessment prior to relicensing.
It can be readily appreciated that there is a clear discrepancy
between clinical guidelines and the more stringent requirements
that must be met for relicensing for aircrew. Although the current
ESC/EACTS guidelines recommend revascularization for >50%
stenosis within the LMS and >70% stenosis for other locations
for aircrew relicensing, complete coronary tree assessment is
Table 2: Follow-up investigations after coronary
revascularization
Items Value
Exercise ECG No myocardial ischaemia
No conduction disturbances
Echocardiogram No dyskinesia, no akinesia
LV biplane ejection fraction >_50%
Holter ECG 24 h No significant rhythm disturbances
After PCI Myocardial perfusion scan
Alternatively: stress echocardiogram
After CABG Within 5 years of surgery: perfusion scan
or equivalent
If any doubt about perfusion Myocardial perfusion scan
Symptoms or signs
of ischaemia
In all cases, coronary angiography
at any time
CABG: coronary artery bypass grafting; ECG: electrocardiogram; LV: left
ventricular; PCI: percutaneous coronary intervention.
Table 1: Follow-up investigations after aortic valve surgery
Items Value
Prosthetic valve function DPmean at rest <20 mmHg
Transvalvular flow pattern and in LVOT Laminar
Dimensions of sinus portion and aorta <4 cm and <4.5 cm,
respectively
Other heart valves No pathologies
Dimensions of the heart chambers LVEDD <5.6 cm
LV muscle mass, free wall and septum <1.1 cm
LV biplane ejection fraction >_50%
No rhythm disturbances 48 h Holter recording
LV: left ventricular; LVOT: left ventricular outflow tract; LVEDD: left
ventricular end-diastolic diameter.
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mandatory and any untreated stenosis >30% in the LMS or prox-
imal LAD is not acceptable. Residual, non-clinically significant,
CAD must therefore be considered for revascularization in pilots
and other aircrew. This presents a real challenge to surgeons as
surgical intervention on a stenosis of <50% stenosis in the LMS
and <70% stenosis in any other coronary vessel is not recom-
mended, as the remaining competitive flow from the native ves-
sel is likely to lead to an early graft failure.
Aortic surgery: ascending aorta, aortic arch and
thoracic aorta
Pilot applicants with an aneurysm of the thoracic aorta may be
assessed as fit, subject to satisfactory cardiological evaluation and
regular follow-up. They may be assessed as fit after surgery for a
thoracic aortic aneurysm subject to satisfactory cardiological and
surgical evaluation to exclude the presence of CAD [8].
Aortic aneurysm involves dilation of the aorta, and in one-sixth of
cases, it involves more than 1 segment. The condition is 4 times
more common in men aged >55 years than in women. The preva-
lence in this age group is 3%. A luminal diameter >5 cm is associated
with a significant increase in risk of rupture. Thoracic aneurysms
show less age-related increase in incidence, the descending, ascend-
ing and arch portions being involved in that order [1]. An ascending
aortic diameter >5.5 cm, a sinus portion of >5.5 cm or a growing
rate >0.5 cm/year are conservative indications for surgery in the ab-
sence of concomitant bicuspid aortic valve disease or connective tis-
sue disorders [14, 20] (Tables 3 and 4). More details to operative
indications were summarized earlier [14, 21, 22].
Genetic and congenital cardiac diseases
Congenital connective tissue disorders such as Marfan’s syndrome,
Ehlers–Danlos and Loeys-Dietz are uniformly assessed as unfit in
pilot applicants. This is often due to the wider skeletal and systemic
manifestations of these conditions in addition to their cardiac dis-
ease. In case of late presentation in pilots and other aircrew, mild
forms of disease may be acceptable, if no systemic manifestation
exceeds the acceptable regulatory requirements. Usual clinical
management (Table 2) should be followed in the first instance.
Common congenital cardiac diseases may be compatible with
pilot licensing, usually if mild or if surgically corrected in child-
hood or early teens. Cyanotic heart disease is universally incom-
patible with aircrew duties. Common congenital cardiac disease
that may present in aircrew includes coarctation of the aorta,
Table 3: Management of the aortic dilation in relationship to diameter, comorbidities and concomitant surgical procedures
Diameter (cm) of ascending aorta Condition Action
Any At the time of diagnosis of Marfan syndrome TTE then repeat TTE 6 months after to determine the
rate of enlargement of the aorta
>4.0 All, asymptomatic Search for connective tissue disorder
Initiate ß-blocker therapy
Strict blood pressure control <120/80 mmHg
Moderately restrict physical activity
Provide pregnancy counselling
Yearly imaging with TTE and/or CT/MRI
>4.0 Bicuspid aortic valve Yearly imaging with TTE and/or CT/MRI
Initiate ß-blocker therapy
>4.0 Women with Marfan Operative treatment: repair aortic root and replace
ascending aorta
>4.2 by TOE (internal diameter) Connective tissue disorder Operative treatment
Loeys–Dietz syndrome>4.4 by CT/MRI (external diameter)
TGFBR1/TGFBR2 mutation
Desired pregnancy
Family history of aortic dissection
Growth >0.5 cm/year
>4.5 Concomitant aortic valve surgery Operative treatment
<5.0 In Marfan patients: if maximal cross-sectional area (cm2)
of root or ascending aorta divided by patient’s
height (m) exceeds a ratio of 10
Operative treatment
>5.0 Any connective tissue disorder Operative treatment: repair aortic root and replace
ascending aortaBicuspid aortic valve
>5.5 All, asymptomatic Operative treatment
CT: computed tomography; MRI: magnetic resonance imaging; TOE: transoesophageal echocardiography; TTE: transthoracic echocardiography.
Table 4: Management of the aortic arch dilation in relation-
ship to diameter
Diameter (cm)
of aortic arch
Condition Action
<4.0 All CT or MRI every 12 months
>4.0 All CT or MRI every 6 months
>5.5 Patients with low
operative risk with
isolated degenerative
or atherosclerotic
aneurysm
Operative treatment
CT: computed tomography; MRI: magnetic resonance imaging.
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patent ductus arteriosus (PDA), hypertrophic cardiomyopathy
and tetralogy of Fallot (ToF).
In individuals with coarctation, unrestricted certification may
be considered in those who have had an operative repair and
are normotensive, provided the operation was performed be-
tween age 12 and 14 and regular follow-up with transthoracic
echocardiography has been performed [1, 3]. Concomitant dila-
tion of the ascending aorta is a disqualifying finding. There are
no data available with regard to postoperative evolution of re-
paired or native coarctation under high +Gz environment and a
history of coarctation is a disqualifying condition in those wishing
to undertake high-performance or military flying.
PDA closure is a safe procedure with an excellent long-term
prognosis; 25-year mortality after surgical closure is <1% with no
late deaths reported. However, PDA is associated with bicuspid
aortic valve, subaortic stenosis, pulmonary stenosis and aortic
root disease, all of which may preclude initial, or renewal, of air-
crew licensing. These associated conditions must be assessed as
part of the aviation medicine consideration in patients with prior
surgical intervention for PDA. If the applicant is free of additional
pathology, unrestricted certification may be considered in those
with a history of PDA [23].
Hypertrophic cardiomyopathy has a prevalence of about 1 in
500 adults. Although often asymptomatic, 1–2% die each year,
half of them suddenly and usually due to ventricular arrhythmia,
thromboembolism and heart failure. Risk factors for sudden car-
diac death include previous cardiac event, family history of sud-
den death, stroke at young age, ventricular tachycardia,
abnormal blood pressure response (a fall of >20 mmHg from
peak pressure) on exercise electrocardiogram, left ventricular wall
thickness >_30 mm and subaortic gradient >_30 mmHg [24]. Half of
the sudden deaths occurring in young male athletes >35 years of
age are due to the condition. Atrial fibrillation may prove incapa-
citating and is a disqualifying condition. Asymptomatic civil ap-
plicants are generally assessed as unfit or required to be
restricted to multicrew operation [1, 3]. Hypertrophic cardiomy-
opathy is a disqualifying condition for military aircrew applicants.
ToF is probably the most complex congenital heart condition
that would be considered for (limited) aircrew licensing. The
operated ToF has a similar survival rate as the normal population
[25] but is associated with a steep increase in the incidence of
ventricular tachycardia, sudden death and atrial tachyarrhythmia
around 20 years following surgery [26]. This presents challenges
in the aviation environment. If operated on before the age of
12 years, with no evidence of residual right ventricular hypertro-
phy, pulmonary regurgitation or ventricular arrhythmia and sub-
ject to regular monitoring by a cardiologist may allow pilot
applicants initial unrestricted certification until the age of
40 years. If >40 years, ToF is not compatible with unrestricted cer-
tification in any environment and will result in OML/OSL restric-
tions at a minimum. ToF is a disqualifying condition for military
aircrew applicants.
DISCUSSION
Cardiac surgery need not be the death knell for pilots’ flying
careers, even for professional pilots. However, a prolonged
period of observation and intensive postoperative investigation
is mandatory and return to flying is not considered earlier
than 6 months postoperatively. Sternum stability after median
sternotomy will be assessed clinically in aircrew as in the general
population. Should a suspicion of sternal malunion arise at this
stage, a computed tomography scan might be considered. Pilots
who have undergone cardiac surgery and meet the regulatory re-
quirements may be considered ‘fit to fly’ by the AMS. We
emphasize the importance of documentation of all lesions as per
Part-MED [8] to avoid any unnecessary licensing restrictions
thereafter.
In valvular surgery, we would highlight the central importance
of biological prostheses with high-flow profile. Furthermore,
stentless implants may be preferred when applicable over stented
ones due to the improved coronary flow profile [6, 7].
Nevertheless, newer stented bioprostheses with improved
haemodynamic characteristics shall be considered as well. Redo
valve surgery must be planned well ahead, before clinical mani-
festations jeopardize the pilot’s ability to fulfil the privileges of his
license. Surgeons and AMEs should not wait for licensing dis-
qualification due to structural valve disease and plan the redo
surgery pre-emptively. We view EASA’s approach towards mech-
anical valves and the associated INR monitoring policy with con-
cern as we believe it lacks evidence to assure the INR is indeed
stable. We believe, in its current form, the risk of thromboembol-
ism, in particular, does not meet the usual standard applied
under the 1% safety rule for sudden incapacitation.
Assessment and management of aircrew, and pilots being con-
sidered for, or having undergone CABG is almost certainly going
to increase significantly for both the AME and the surgeon, as
pilots fly longer and non-invasive investigations for CAD improve
[27]. The superiority of CABG over PCI for revascularization of left
main, left anterior descending and multivessel disease has been
demonstrated and is well documented [10]. We note, with con-
cern, that neither bilateral internal mammary artery graft use in-
stead of a single internal mammary artery graft nor total arterial
revascularization is mentioned in the current EASA regulations.
Additionally, PCI is known to be less effective than surgery in ob-
taining full revascularization in complex CAD, which is a criterion
for revalidation in aircrew and the numerous iterations of the
SYNTAX study offer substantial evidence for an optimized surgi-
cal choice of procedure [28, 29].
There is clearly significant debate to be had with regard to the
evidence for whether intervention on untreated stenosis >30% is
acceptable; there is no evidence of any benefit in grafting such
coronary lesions [10] and with regard to revascularization, the
current ESC/EACTS guidelines recommend surgical intervention
only in stenosis levels of >50% for the left main and >70% for
other localizations in the coronary tree. Revascularization of <50%
stenosis in the left main and <70% stenosis in any other coronary
vessel is not recommended, as the remaining competitive flow
from the native vessel is likely to lead to an early graft failure. No
surgical evidence supports revascularization of stenoses <70%
(<50% for the LMS) in any vessel including graft. Neither does it
apply to PCI. The radial artery should not be used to graft stenoses
less than critical (<90%) [18, 19]. Interestingly in a population
where risk assessment is paramount, graft flow measurement
upon revascularization completion is not mentioned in current
aviation guidelines, and as this quality control item becomes in-
creasingly routine in surgery, threshold values for the graft flow
and pulsatile indices will need to be defined and included in the
regulatory requirements for aircrew.
Aortic surgery and congenital cardiac diseases are fortunately
rare among the aircrew population, especially pilots, but never-
theless require the same systematic approach based on current
evidence and surgical options [14, 20–22].
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CONCLUSIONS
To fly as a pilot after cardiac surgery is possible, but special
attention to perioperative planning is mandatory. Choice of pro-
cedure (e.g. full revascularization and arterial grafts) and pros-
thetic material (e.g. stentless bioprosthesis) are crucial for license
renewal. Licensing restrictions are likely to apply and the postop-
erative follow-up requires a tight scheduling. Enhanced know-
ledge transfer between the surgical and cardiological societies
and the aviation authorities ought to support future revisions of
the medical regulations for flight crew licensing. The cardiac
surgeon should always consider the professional ramifications of
the surgical management of pilots and maintain close liaison and
communication with the pilot’s AME prior to and following
cardiac surgery.
Conflict of interest: none declared.
REFERENCES
[1] International Civil Aviation Organization ICAO. Manual of Civil Aviation
Medicine, 3rd edn. Quebec, Canada: ICAO, 2012.
[2] UK Civil Aviation Authority CAA. Personal Licenses and Training,
Medical. 2014. http://www.caa.co.uk/medical/ (August 2017, date last
accessed).
[3] Joint Aviation Authorities JAA. Manual of Civil Aviation Medicine.
Colorado, USA: Global Engineering Documents, 2009.
[4] UK Civil Aviation Authority CAA. Personal Licenses and Training,
Medical CAP 1127 P. 2013. http://www.caa.co.uk/Aeromedical-
Examiners/Medical-standards/ (August 2017, date last accessed).
[5] Federal Aviation Administration FAA. Acceleration in Aviation: G-Force.
Oklahoma City, OK: FAA. 2015. https://www.faa.gov/pilots/safety/pilotsa-
fetybrochures/media/acceleration.pdf (August 2017, date last accessed).
[6] Kuehnel RU, Puchner R, Pohl A, Wendt MO, Hartrumpf M, Pohl M et al.
Characteristic resistance curves of aortic valve substitutes facilitate indi-
vidualized decision for a particular type. Eur J Cardiothorac Surg 2005;
27:450–5; discussion 455.
[7] Bakhtiary F, Schiemann M, Dzemali O, Wittlinger T, Doss M, Ackermann
H et al. Stentless bioprostheses improve postoperative coronary flow
more than stented prostheses after valve replacement for aortic stenosis.
J Thorac Cardiovasc Surg 2006;131:883–8.
[8] European Aviation Safety Agency. Acceptable Means of Compliance and
Guidance Material to Part-MED. Cologne, Germany: European Aviation
Safety Agency Headquarters, 2011.
[9] European Aviation Safety Agency. Acceptable Means of Compliance and
Guidance Material to Part-MED—Amendment 1. Cologne, Germany:
European Aviation Safety Agency Headquarters, 2013.
[10] Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014
ESC/EACTS Guidelines on myocardial revascularization: the task force on
myocardial revascularization of the European Society of Cardiology
(ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS). Eur J Cardiothorac Surg 2014;46:517–92.
[11] Mascherbauer J. The 2014 AHA/ACC valve disease guideline: new stages
of disease, new treatment options, and a call for earlier intervention.
Wien Klin Wochenschr 2014;126:458–9.
[12] Fedak P, Verma S, David TE, Leask RL, Weisel RD, Butany J. Clinical and
pathophysiological implications of a bicuspid aortic valve. Circulation
2002;106:900–4.
[13] Syburra T, Schnuriger H, Kwiatkowski B, Graves K, Reuthebuch O,
Genoni M. Pilot licensing after aortic valve surgery. J Heart Valve Dis
2010;19:383–8.
[14] Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G,
Baumgartner H et al. Guidelines on the management of valvular heart
disease (version 2012): the Joint task force on the management of valvu-
lar heart disease of the European Society of Cardiology (ESC) and the
European Association for Cardio-Thoracic Surgery (EACTS). Eur J
Cardiothorac Surg 2012;42:S1–44.
[15] Fries R, Wendler O, Schieffer H, Schafers HJ. Comparative rest and exer-
cise hemodynamics of 23-mm stentless versus 23-mm stented aortic
bioprostheses. Ann Thorac Surg 2000;69:817–22.
[16] Silberman S, Shaheen J, Merin O, Fink D, Shapira N, Liviatan-Strauss N
et al. Exercise hemodynamics of aortic prostheses: comparison between
stentless bioprostheses and mechanical valves. Ann Thorac Surg 2001;
72:1217–21.
[17] Milano AD, Blanzola C, Mecozzi G, D’Alfonso A, De Carlo M, Nardi C
et al. Hemodynamic performance of stented and stentless aortic bio-
prostheses. Ann Thorac Surg 2001;72:33–8.
[18] Glineur D, Hanet C. Competitive flow and arterial graft a word of cau-
tion. Eur J Cardiothorac Surg 2012;41:768–9.
[19] Glineur D, Hanet C. Competitive flow in coronary bypass surgery: is it a
problem? Curr Opin Cardiol 2012;27:620–8.
[20] Treasure T, Takkenberg JJ, Pepper J. Surgical management of aortic root
disease in Marfan syndrome and other congenital disorders associated
with aortic root aneurysms. Heart 2014;100:1571–6.
[21] Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton
RA et al. 2014 AHA/ACC guideline for the management of patients with
valvular heart disease: a report of the American College of Cardiology/
American Heart Association task force on practice guidelines.
Circulation 2014;129:e521–643.
[22] Cozijnsen L, Braam RL, Waalewijn RA, Schepens MAAM, Loeys BL, van
Oosterhout MFM et al. What is new in dilatation of the ascending aorta?
Review of current literature and practical advice for the cardiologist.
Circulation 2011;123:924–8.
[23] International Civil Aviation Organization ICAO. Manual of Civil Aviation
Medicine, Part I Licensing Practices—Preliminary Edition. Quebec,
Canada: ICAO, 2008.
[24] Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P
et al. 2014 ESC Guidelines on diagnosis and management of hyper-
trophic cardiomyopathy: the task force for the diagnosis and manage-
ment of hypertrophic cardiomyopathy of the European Society of
Cardiology (ESC). Eur Heart J 2014;35:2733–79.
[25] Murphy JG, Gersh BJ, Mair DD, Fuster V, McGoon MD, Ilstrup DM et al.
Long-term outcome in patients undergoing surgical repair of tetralogy
of Fallot. N Engl J Med 1993;329:593–9.
[26] Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C et al.
Risk factors for arrhythmia and sudden cardiac death late after repair of
tetralogy of Fallot: a multicentre study. Lancet 2000;356:975–81.
[27] Pavitt CW, Harron K, Lindsay AC, Ray R, Zielke S, Gordon D et al.
Deriving coronary artery calcium scores from CT coronary angiography:
a proposed algorithm for evaluating stable chest pain. Int J Cardiovasc
Imaging 2014;30:1135–43.
[28] Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A
et al. Coronary artery bypass graft surgery versus percutaneous coronary
intervention in patients with three-vessel disease and left main coronary
disease: 5-year follow-up of the randomised, clinical SYNTAX trial.
Lancet 2013;381:629–38.
[29] Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass
grafting vs percutaneous coronary intervention and long-term mortality and
morbidity in multivessel disease: meta-analysis of randomized clinical trials
of the arterial grafting and stenting era. JAMA Intern Med 2014;174:223–30.
[30] Fischer U. Der Kreislauf unter Beschleunigung. Ro¨ntgenaufnahmen beim
Affen. Luftfahrtmedizin 1937;2:1–13.
R
EV
IE
W
7T. Syburra et al. / European Journal of Cardio-Thoracic Surgery
Downloaded from https://academic.oup.com/ejcts/advance-article-abstract/doi/10.1093/ejcts/ezx346/4540607
by Imperial College London Library user
on 09 January 2018
